3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
33
Ovarian Neoplasms
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Metastatic Castration-resistant Prostate Cancer
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms, Castration-Resistant
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Castration-Resistant Prostate Carcinoma
2
Xanthogranuloma, Juvenile
1
Interventions
padeliporfin
5
Nivolumab
5
Ipilimumab
4
Sunitinib
3
Specimen Handling
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Abiraterone Acetate
3
pembrolizumab
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
abiraterone
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Pluvicto
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
vinflunine
1
valrubicin
1
tislelizumab
1
temsirolimus
1
sipuleucel-T
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
olaparib
×
Genitourinary
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled